April 08, 2025

Which Bariatric Surgery Proves Most Effective?

New study finds Roux-en-Y gastric bypass achieves better weight loss outcomes and quality of life than sleeve gastrectomy or adjustable gastric banding in a multi-center randomized controlled trial.

Conexiant

April 08, 2025

Season of Conception May Impact BMI

Preconception cold exposure may enhance brown fat activity and metabolic health.

Conexiant

April 07, 2025

GLP-1, SGLT2 Found to Reduce Alzheimer's Risk

New study finds GLP-1 agonists and SGLT2 inhibitors associated with reduced risk of dementia in type 2 diabetes patients compared to other glucose-lowering medications.

Conexiant

April 07, 2025

Placebos Show Promise for PMS

The success may be linked to patient expectations and transparent communication.

Conexiant

April 04, 2025

Post-COVID Diabetes Risk Higher in Unvaccinated

Compared with a historical cohort of patients hospitalized for influenza, those hospitalized for COVID-19 had a 45% higher post-acute type 2 diabetes risk during delta and a 56% higher risk during omicron.

Conexiant

April 02, 2025

GLP-1 Spending Surged 500% Since 2018

U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.

Conexiant

April 01, 2025

GEM Helps Put T2D in Remission

Researchers highlight evidence-based lifestyle and pharmacologic strategies, including glycemic excursion minimization and tirzepatide, for early glycemic control in adults with type 2 diabetes.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant